Logo

Boehringer Ingelheim’s Cyltezo Pen Receives the US FDA’s Approval for Cyltezo, an Interchangeable Biosimilar to Humira

Share this
Boehringer Ingelheim

Boehringer Ingelheim’s Cyltezo Pen Receives the US FDA’s Approval for Cyltezo, an Interchangeable Biosimilar to Humira

Shots:

  • The US FDA has approved Cyltezo Pen, an autoinjector option of Cyltezo (the US FDA-approved Interchangeable biosimilar to Humira)
  • Additionally, 40mg/0.8mL pre-filled Cyltezo Pen will be available in two, four, and six-pack options on July 1, 2023. Cyltezo was initially approved as a pre-filled syringe, indicated to treat multiple chronic inflammatory diseases incl.  RA, JIA, CD, and PsO
  • Additionally, Cyltezo Pen features a one-button, 3-step activation with 100% drug visibility and a protected needle. In 2021, Cyltezo became the first approved interchangeable biosimilar to treat certain inflammatory diseases

Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim

Related News:- Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions